Kornimate/medical-research-clean huggingface dataset:
peppermint oil for urinary retention

Conditions: Urinary Retention

Summary: a randomized controlled study will be conducted, with two arms. postpartum women experiencing urinary retention will be randomized into one of the two following arms: * arm 1: subjects will be exposed to vapor of peppermint oil * arm 2: subjects will be exposed to vapor of placebo (mineral oil) outcome variables include resolution of urinary retention, time to spontaneous urination, volume of spontaneous urination, frequency of urinary catheterization, and patient satisfaction.

the purpose of the study is to determine if the use of peppermint oil among postpartum women experiencing urinary retention will increase spontaneous urination and decrease the need for catheterization. a randomized controlled study will be conducted, with two arms. subjects will be randomized into one of the two following arms: * arm 1: subjects will be exposed to vapor of peppermint oil * arm 2: subjects will be exposed to vapor of placebo (mineral oil) outcome variables include resolution of urinary retention, time to spontaneous urination, volume of spontaneous urination, frequency of urinary catheterization, and patient satisfaction.

Eligibility criteria:
inclusion criteria: * 1. 18 years old or older 2. english speaking 3. admitted to bethesda north mom baby unit 4. postpartum 5. experiencing urinary retention - defined as meeting at least one of the following criteria: * more than 6 hours after delivery or foley catheter removal without being able to spontaneously void * symptomatic urinary retention without being able to spontaneously void * change in fundal height or position without being able to spontaneously void 6. bladder scan showing bladder containing 400ml or more urine exclusion criteria: 1. allergy to peppermint 2. asthma 3. active herpes lesions 4. seizure disorder 5. not able to void in toilet (ex: requiring use of bed pan to void)

Keywords: peppermint oil postpartum
wharton's jelly eye drops in the treatment of chronic keratitis

Conditions: Keratitis, Ulcerative; Corneal Ulcer

Summary: the purpose of this open, non-comparative, multicenter trial is to assess the impact of eye drops made of wharton's jelly extract in the treatment of chronic keratitis that failed available therapies.


Eligibility criteria:
inclusion criteria: * men or women between 18 and 70 years old. * persistent corneal ulceration. * resistance to medical treatment for more than one month or recurrence after medical treatment. * patient who underwent a wash-out period of 15 days with no use of eye drops with preservative. * patient with dry eye treatments that can be kept: tear substitutes, cyclosporine. * informed and consenting patient. * patient affiliated to a social security system or beneficiary of such a system. exclusion criteria: * patient with active infectious or traumatic keratitis such as burns. * patient with herpetic keratitis. * patient currently wearing contact lens, including scleral lenses concomitant with the treatment. * patient currently treated with nsaids in eye drops or any eye drops containing preservatives. * patient treated with antibiotic, anti-viral or anti-parasitic eye drops; with autologous or allogeneic serum; with platelet derivatives; with eye drops claiming healing properties; with eye drops containing growth factors, hyaluronic acid or trehalose. * patient with hypersensitivity to fluorescein. * patient with identified causes for keratitis for which discontinuation of medical treatment is beneficial. * monophthalmic patients. * persons deprived of liberty by a judicial or administrative decision. * adults who are subject to a legal protection measure or who are unable to express their consent. * pregnant woman.
epo906 therapy in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer

Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms

Summary: this study will examine whether the new investigational drug epo906, given by intravenous infusion (iv directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. recruitment in the united states is complete but the study is still enrolling in other countries.


Eligibility criteria:
inclusion criteria: the following patients may be eligible for the study: * histologically or cytologically documented evidence of ovarian, primary fallopian or primary peritoneal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) * must have a life expectancy of greater than three (3) months * prior failure to respond following front-line treatment with a taxane and platinum (or a combination therapy) may be eligible. exclusion criteria: the following patients are not eligible for the study: * patients with radiation therapy or chemotherapy within the last four weeks * patients who have had any chemotherapy not containing a taxane and platinum for their disease * patients with borderline ovarian and macropapillary tumors * patients with unresolved bowel obstruction * patients with symptomatic cns metastases or leptomeningeal involvement * patients with any peripheral neuropathy or unresolved diarrhea greater than grade 1 * patients with severe cardiac insufficiency * patients taking coumadin or other warfarin-containing agents with the exception of low dose coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports * history of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ * patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae * hiv+ patients * pregnant or lactating females.

Keywords: ovarian ovary peritoneal cancer fallopian cancer cancer tumor tumour neoplasm carcinoma intravenous epothilone
characterisation of fractionated electrograms critical for maintenance of atrial fibrillation (af)

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to characterise which fractionated electrogram morphologies are important to target in the catheter ablation of atrial fibrillation.


Eligibility criteria:
inclusion criteria: * patients with persistent af listed for first time catheter ablation exclusion criteria: * age \< 18 years * pregnancy * contraindications to procedure * recent myocardial infarction, coronary intervention, or cardiac surgery

Keywords: af catheter ablation fractionated electrogram complex fractionated atrial electrogram (cfae)
effect of semi-recumbent position on treatment of shoulder pain seen after laparoscopic cholecystectomy

Conditions: Shoulder Pain

Summary: this study was carried out to determine the effect of placing the semi-recumbent position in reducing pain in patients who developed shoulder pain after laparoscopic cholecystectomy. ho: the application of the semi-recumbent position to patients who develop shoulder pain after laparoscopic cholecystectomy has no effect on reducing pain. h1: the application of semi-recumbent position in patients who develop shoulder pain after laparoscopic cholecystectomy has an effect on reducing pain.

in addition to pharmacological interventions for the relief of postoperative complications such as pain in patients undergoing laparoscopic cholecystectomy, non-pharmacological applications; it is evaluated that it will be beneficial in increasing patient satisfaction, reducing the need for analgesic drugs, reducing the cost of hospitalization due to the side effects of drugs and increasing the quality of care. with the results of this research, it is evaluated that the effect of positioning, which is one of the independent activities of nurses who base their care on evidence-based practices, on pain will be beneficial to increase the evidence-based nursing knowledge in the literature.

Eligibility criteria:
inclusion criteria: * those who had surgery with laparoscopic cholecystectomy * those between the ages of 18-65, * patients in asa i-ii group * patients undergoing general anesthesia exclusion criteria: * epidural analgesia after surgery * patients with reactive airway diseases such as chronic obstructive pulmonary disease (copd), bronchitis, emphysema * conversion to open abdominal surgery during laparoscopic cholecystectomy

Keywords: laparoscopic cholecystectomy shoulder pain semi-recumbent position pain
mri guided management of occlusive peripheral arterial disease

Conditions: Peripheral Vascular Diseases

Summary: the goal of this observational study is to identify which plaque lesions in patients with peripheral arterial disease are impenetrable and to determine which devices minimize vessel wall injury. patients undergoing intervention will have an mri scan prior to their planned percutaneous vascular intervention to assess the plaque and predict procedural difficulty. patients undergoing lower limb amputation due to peripheral arterial disease will have their limbs included into a second arm of the study the limb will undergo an mri scan to assess the plaque. the investigator will then test two different devices and assess the effects of these devices on the vessel wall.

please see attached study protocol.

Eligibility criteria:
inclusion criteria: a. general inclusion criteria: i. all patients will be ≥ 40 years old with pad (rutherford category 4, 5, 6) b. anatomic inclusion criteria: i. at least 1 target lesion below-the-knee in native vessels in one or both limbs ii. target lesion reference vessel diameter between 2.0 - 4.0 mm by investigator visual estimate iii. target lesion with \> 50% stenosis by investigator visual estimate exclusion criteria: a. general exclusion criteria: i. rutherford category 0, 1, 2, 3 of target limb, failure or refusal to provide written informed consent, mri contraindications b. anatomic exclusion criteria: ii. aim 2 only - chronic total occlusions

Keywords: mri guided management of occlusive peripheral arterial disease pad peripheral vascular disease pvi mri mra
propellers flaps for meningomylocele defects

Conditions: Meningocele; Meningomyelocele

Summary: to evaluate reliability of free style propeller perforator flap for coverage mmc soft tissue defect follow a well-established step that overcome the usual problem of pedicled perforators propellers flaps.

meningomyelocele is a serious congenital birth defect that not only affect mortality and morbidity of neonate but also a lifelong health problem. the estimated incidence of spina bifida is 1-2 cases per 1000 population. meningomylocele soft tissue defect reconstruction is considered a lifesaving procedure , the ideal coverage technique should be time limited , reliable and allow healing line to be away from repair of the dura . all of these criteria are available in the selection of free style propeller perforator flap as a method of reconstruction.

Eligibility criteria:
inclusion criteria: * all cases with dorsolumbar meningomyelocele and age up to 6 months exclusion criteria: * infants older than 6 months * concomitant congenital anomalies * concomitant spinal kyphosis

Keywords: reconstructive surgical procedures / adverse effects meningomyelocele / surgery
a naturalistic prospective study of treatment effectiveness for attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD)

Summary: to determine if there is a clinically and statistically significant difference between oros-mph and ir mph in adha and odd symptoms by the parent completed snap-iv. it is hypothesized that oros-mph is superior in improving symptom outcomes overall, remission rate, functional improvement, quality of life and persistence with medication over time.

this one-year prospective observational study is designed to evaluate and compare outcomes effectiveness between oros-mph and ir mph in adha and odd symptoms at the adhd clinic of the british columbia children's and women's health centre. a practical clinical trial is valuable because it has the potential to provide us the information which represents the actual outcomes in real settings. the primary objective of this study is to analyze the treatment outcomes of adhd patients under conditions of routine clinical practice. patients will, therefore, be treated according to the current practice of each participating physician, with the exception of several additional rating scales which are snap-iv, strengths and difficulties questionnaire, weiss functional impairment rating scale (wfirs)-parent, child health and illness profile (chip), eq-5d, parent/caregiver questionnaire, adhd side effect checklist, adolescent diversion questionnaire, adaptive behavior assessment system-second edition (abas-2) and clinic global impressions. patients will be assessed at baseline and 12 months regardless of whether the original treatment is continued. if a patient terminates the study early, all assessments that are normally collected at the end of the study will be collected at the time of termination. only patients with pre and post data will be included in the analysis. results of this study are expected to make breakthrough on the treatment of adhd in practice; and, particularly, information which come out from this study is not currently available from other researches.

Eligibility criteria:
inclusion criteria: 1. patients between the ages of 6 and 18. 2. enrolled in school with at least 1 school year remaining before completion of high school. 3. current drug therapy with either a ir mph or oros mph. exclusion criteria: 1. parent/caregiver unable or unwilling to provide written informed consent. 2. child unable or unwilling to provide assent (for children aged 7 years). 3. parent/caregiver unable or unwilling to complete questionnaires. 4. child unable or unwilling to complete questionnaires adhd is considered by the clinician to be secondary to another more serious disorder such as personality disorder, substance abuse, bipolar disorder, autism, or mental handicap. 5. participation in another treatment study.

Keywords: adhd effectiveness odd
speech performance of rugby players when using different types of mouthguard

Conditions: Speech

Summary: participation in contact sports is linked to an increased risk of dental injuries. to reduce the risk and severity of sports-related dental injuries, mouthguards are often recommended to be worn during training and competition. however, athletes often complain that they cannot talk properly when using mouthguards. it is hypothesized that speech performance differs when using different types of mouthguards. a group of female national rugby players will be asked to pronounce four malay words with plosive sounds (/p/, /b/, /d/ and /t/) repeatedly in three conditions: (i) when not using any mouthguard, (ii) when using 'boil and bite' mouthguard, and (iii) when using custom-fitted mouthguard. the sounds will be recorded for spectrographic analysis. the difference in mean voice onset time between conditions will be assessed.


Eligibility criteria:
inclusion criteria: * adult female aged 18 years old and older * currently representing the nation and participating actively in rugby * native speakers of malay (national language) exclusion criteria: * did not play rugby within the last six months * edentulism * used a mouthguard, orthodontic appliance or removable prosthodontics appliance within the last six months * known history of allergy to polymers * medical problems (asa classification 3 and above)

Keywords: dental trauma rugby mouthguard speech contact sports
corneal epithelial autograft for pterygium

Conditions: Pterygium

Summary: the purpose of the study is to explore whether femtosecond laser-assisted cornea epithelial autograft is more effective than limbal conjunctival autograft for ocular surface reconstruction after excision of pterygium.


Eligibility criteria:
inclusion criteria: 1. age between 18 to 80 years old; 2. primary pterygium, scheduled for elective surgical excision; 3. pterygium encroaching from the nasal side onto the cornea, with less than 180° limbal involvement and without approaching the central visual axis (pupil area); 4. morphologically intact palisades of vogt in a given limbal region; 5. absence of any one of the following structures in the limbal region underneath the pterygium: (1) epithelial basal cells with dark cytoplasm and reflective cell borders; (2) at least two prominent palisade ridge structures; (3) at least one circular and/or oval-shaped focal stromal projection; 6. informed consent signed by patient or legal guardian; having the ability to comply with study assessments for the full duration of the study. exclusion criteria: 1. limbal stem cell deficiency by ocular surface disorders other than pterygium; 2. inability to determine whether the palisades of vogt underneath the pterygium is absent or not using in vivo confocal microscopy; 3. high myopia with a spherical equivalent of -15.0 d or less; 4. corneal or ocular surface infection within 30 days prior to study entry; 5. ocular surface malignancy; 6. uncontrolled diabetes with most recent hemoglobin a1c greater than 8.5%; 7. renal failure with creatinine clearance\< 25ml/min; 8. alanine aminotransferase \> 40iu/l, or aspartate aminotransferase \> 40iu/l; 9. platelet levels \ 450,000 per microliter; 10. hemoglobin \< 12.0 g/dl (male) or \< 11.0 g/dl (female); 11. prothrombin time \> 16s and activated partial thrombin time \> 35s in patients not accepting anticoagulant therapy; an international normalized ratio greater than 3 in patients accepting anticoagulant therapy; 12. pregnancy (positive test) or lactation; 13. participation in another simultaneous medical investigation or clinical trial; 14. severe cicatricial eye disease; 15. ocular comorbidities that affect the prognosis of transplantation, such as advanced glaucoma or retinal diseases; 16. severe dry eye disease as determined by schirmer's test \< 2mm at least in one eye; 17. any medical or social condition that in the judgement of the investigator would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent; 18. signs of current infection, including fever and treatment with antibiotics; 19. active immunological diseases; 20. history of allo-limbal transplantation, penetrating keratoplasty or anti-glaucoma filtering surgeries.
effect of pneumatic tourniquet on arm swelling after lymph node removal

Conditions: Healthy Subject

Summary: the purpose of the proposed study is to evaluate the acute impact of swelling caused by low-pressure tourniquet use in the setting of ipsilateral prior axillary lymph node dissection and the change in swelling reduction following tourniquet use in three limb postures versus healthy volunteers.

primary objectives: i. to evaluate reduction in swelling and safety of tourniquet use in patients with prior axillary lymph node dissection outline: participants raise their arm for 15 minutes, then wear a tourniquet inflated for 25 minutes. hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position. procedure: participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.

Eligibility criteria:
inclusion criteria: * have previously undergone axillary lymph node dissection * or healthy volunteers exclusion criteria: * have new-onset lymphedema of the involved limb. * infection including cellulitis * trauma or planned axillary surgery within 6 months of participation * any prior axillary radiation
evaluate the rotator cuff repair with "inspace" vs without "inspace"

Conditions: Repair of a Cuff Tear

Summary: evaluate the re-rupture rate 12 months following the intervention in a group with and a group without a spacer


Eligibility criteria:
inclusion criteria: * first intention of the rotator cuff * repairable supraspinatus and infraspinatus type 2 rupture (according to the patte classification, tendon retraction at the top of the humeral head) * no surgical history * patient who has given his participation agreement to participate in the observational study after information by the surgeon, * patient living in france and having the capacity to answer alone to the survey. * subject affiliated to a social security scheme * lack of participation in another clinical study exclusion criteria: * major subject protected by law, under curatorship or tutorship * known allergy to inspace medical device materials (pla and -θ-caprolactone copolymer) * osteoporosis * damaged cartilage * isolated rupture of the suprascapularis * glenohumeral instability * pseudo-paralytic shoulder- infection * necrosis * major joint trauma * pregnant or breastfeeding women
parenchymal sparing hepatectomy in post-chemotherapy liver atrophy

Conditions: Colorectal Cancer Stage IV

Summary: major hepatectomy in patients with colorectal liver metastases (clm) and post-chemotherapy liver atrophy is associated with increased complications. whether the performance of parenchymal-sparing hepatectomy (psh) in those patients can be safer is unknown. the aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing psh for clm. for this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.

patients affected by clms and trated with neoadjuvant systemic chemotherapy and then hepatectomy were reviewed with the intent to assess the occurrence of liver atrophy, which is a sign of liver dysfunction and a source of morbidity expecially in patients treated with major or extended hepatectomy. whether the performance of parenchymal-sparing hepatectomy (psh) in those patients can be safer is unknown. then, we planned to review our cases with the above mentioned endpoint.

Eligibility criteria:
inclusion criteria: * consecutive patients with multiple clms treated with preoperative chemotherapy and parenchymal sparing surgery; * only patients with available volumetry of the pre- and post-chemotherapy abdominal enhanced computed tomography (ct) images; exclusion criteria: * patients who underwent preoperative pve; * patients treated by major hepatectomies; patients treated with thermal ablation alone or in association with hepatic resection.
comparison of human insulin produced by the current process and the nn729 process in type 1 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in asia and oceania. the aim of this trial is to compare the efficacy and safety of human insulin produced by the current process and the nn729 process in type 1 diabetes.


Eligibility criteria:
inclusion criteria: * duration of diabetes for at least 12 months * basal/bolus treatment with human insulin for at least 2 months preceding trial start * body mass index (bmi) lesser than or equal to 35.0 kg/m2 * hba1c lesser than or equal to 12.0% exclusion criteria: * proliferative retinopathy or maculopathy requiring acute treatment or laser treatment within the last 6 months * any condition that the investigator and/or sponsor feel would interfere with trial participation * known or suspected allergy against trial product or related products